search
Back to results

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2, Healthy

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
semaglutide
placebo
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

20 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male Japanese and Caucasian subjects
  • Age between 20 and 55 years (both inclusive) at the time of signing informed consent
  • Body weight of equal to or above 54.0 kg
  • Body mass index (BMI) between 20.0 and 25.0 kg/m^2 (both inclusive)
  • Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0%
  • For Japanese subjects only: both parents Japanese
  • For Caucasian subjects only: both parents Caucasian

Exclusion Criteria:

  • Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Calcitonin above or equal to 50 ng/L
  • History of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one glass) of wine or Japanese sake, or approximately 20 mL of spirits
  • Smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure
  • Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior to Visit 2 (randomisation). The use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted

Sites / Locations

  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Semaglutide 0.5 mg

Semaglutide placebo 0.5 mg

Semaglutide 1.0 mg

Semaglutide placebo 1.0 mg

Arm Description

Dose-escalation trial

Dose-escalation trial

Outcomes

Primary Outcome Measures

Area under the plasma semaglutide concentration-time curve

Secondary Outcome Measures

Maximum observed plasma semaglutide concentration at steady state
Change in body weight from baseline to the end of treatment
Number of treatment emergent adverse events (TEAEs) from baseline to follow-up

Full Information

First Posted
May 21, 2014
Last Updated
April 16, 2018
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT02146079
Brief Title
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
Official Title
A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 21, 2014 (Actual)
Primary Completion Date
October 20, 2014 (Actual)
Study Completion Date
October 20, 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and tolerability of semaglutide in healthy male Japanese and Caucasian subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2, Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Semaglutide 0.5 mg
Arm Type
Experimental
Arm Description
Dose-escalation trial
Arm Title
Semaglutide placebo 0.5 mg
Arm Type
Placebo Comparator
Arm Title
Semaglutide 1.0 mg
Arm Type
Experimental
Arm Description
Dose-escalation trial
Arm Title
Semaglutide placebo 1.0 mg
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
semaglutide
Intervention Description
Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
Primary Outcome Measure Information:
Title
Area under the plasma semaglutide concentration-time curve
Time Frame
During a dosing interval (0-168 hours) at steady state
Secondary Outcome Measure Information:
Title
Maximum observed plasma semaglutide concentration at steady state
Time Frame
0-168 hours after the last dose of semaglutide (0.5 and 1.0 mg)
Title
Change in body weight from baseline to the end of treatment
Time Frame
Day 1 of Visit 2 (2-21 days after Visit 1), Day 92
Title
Number of treatment emergent adverse events (TEAEs) from baseline to follow-up
Time Frame
From Day 1 of Visit 2 (2-21 days after Visit 1) to Day 120-127 (Visit 23)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male Japanese and Caucasian subjects Age between 20 and 55 years (both inclusive) at the time of signing informed consent Body weight of equal to or above 54.0 kg Body mass index (BMI) between 20.0 and 25.0 kg/m^2 (both inclusive) Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0% For Japanese subjects only: both parents Japanese For Caucasian subjects only: both parents Caucasian Exclusion Criteria: Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) History of chronic pancreatitis or idiopathic acute pancreatitis Calcitonin above or equal to 50 ng/L History of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one glass) of wine or Japanese sake, or approximately 20 mL of spirits Smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior to Visit 2 (randomisation). The use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
130-0004
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
29536338
Citation
Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Adv Ther. 2018 Apr;35(4):531-544. doi: 10.1007/s12325-018-0677-1. Epub 2018 Mar 13.
Results Reference
result
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

We'll reach out to this number within 24 hrs